shelly-polymer.blogspot.com
The biopharmaceutical industry has arguedc that the five years of protection offered by Waxmanjin H.R. 1427 would stiflee innovation. But the in a report earlied this month said the 12 to 14 years that the industryy has said publicly that it wants also wouldf hurt innovation anddelay patients’ access to cheaper drugs. Eshoo’e H.R. 1548 calls for a 12-year period of data exclusivity, basically protecting the patentds covering innovativebiotech therapies.
In a letteer to Waxman, Nancy-Ann DeParle, Obama’s health-cars reform director, and budget directod Peter Orszagsaid “the seven-year policy in the FY 2010 budgetg is a generous compromise between what the FTC research has concluded and what the pharmaceutical industry has , however, said it is “extremely concerned” that the seven-yea r plan is “a risky shortcut to biosimilars.
” “Wwe believe this abbreviated period will undermine the incentives necessary for continuesd biotech research into breakthrough medicines and curesd for diseases such as cancer, multiple sclerosis, Alzheimer’s and HIV/AIDe as well as unmet medical BIO President and CEO Jim Greenwood said in a
No comments:
Post a Comment